2 results
Approved WMOCompleted
To investigate trastuzmab-paclitaxel in EGFR-mutated NSCLC patients who have overexpression of HER2 and who have progressed on standard TKI-treatment
Approved WMOWill not start
The primary objective of this study is to determine if ambrisentan is effective in delaying disease progression and death in subjects with IPF.Secondary objectives include evaluation of the safety and effect of ambrisentan on development of…